The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage
innate immune effectors through interactions mediated by their fragment crystallizable (Fc) …

Nicotinamide adenine dinucleotide (NAD+) is an essential co-enzyme reported to operate
both intra-and extracellularly. In the extracellular space, NAD+ can elicit signals by binding …

Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action
by engaging the immune system. Unfortunately, cures rarely occur and patients display …

Following the success of rituximab, 2 other anti-CD20 monoclonal antibodies (mAbs),
ofatumumab and obinutuzumab, have entered clinical use. Ofatumumab has enhanced …

The anti-CD28 superagonist antibody TGN1412 caused life-threatening cytokine release
syndrome (CRS) in healthy volunteers, which had not been predicted by preclinical testing …

Many therapeutic antibodies deplete target cells and elicit immunotherapy by engaging
activating Fc gamma receptors (FcγRs) on host effector cells. These antibodies are …

Background Hypoxia is a hallmark of the tumor microenvironment (TME) and in addition to
altering metabolism in cancer cells, it transforms tumor-associated stromal cells. Within the …

FcγRs are key regulators of the immune response, capable of binding to the Fc portion of
IgG Abs and manipulating the behavior of numerous cell types. Through a variety of …

The majority of depleting monoclonal antibody (mAb) drugs elicit responses via Fc-FcγR and
Fc-C1q interactions. Optimal C1q interaction is achieved through hexameric Fc: Fc …

The pan B-cell marker CD20 was cloned more than 3 decades ago. It has been intensively
studied ever since, allowing the specific identification and targeting of B cells facilitating the …